ARCHIVES

Lung Cancer Clinical Trials Cost-Effective Alternative

This article is from The Cancer Letter archive.

Vol. 26 No. 10 | October 31, 2003

Download PDF Visit The Full Archive

Related Articles

Latest U.S. cancer statistics cover 84% of population.

December 5, 2003

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

December 10, 2004

Fox Chase Publishes Its Cancer Survival Data

February 4, 2011

Breast Cancer: Working Group Sets Broad Agenda For Genetic Research

January 10, 1997

New NCI Director Varmus “Glad To Be Back,” Says Goal Is To Control Cancer Through Science

July 16, 2010

NIH Panel Calls for Further Research On End-of-Life Issues.

January 21, 2005